riluzole has been researched along with Movement Disorders in 5 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cotreatment with riluzole (4 mg/kg i." | 1.30 | Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration. ( Brouillet, E; Guyot, MC; Hantraye, P; Mary, V; Palfi, S; Peschanski, M; Riche, D; Stutzmann, JM; Wahl, F, 1997) |
| " In addition, it was checked that this neuroprotective effect of riluzole against systemic 3-nitropropionic acid did not result from a decreased bioavailability of the neurotoxin or a direct action of riluzole on 3-nitropropionic acid-induced inhibition of succinate dehydrogenase." | 1.30 | Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. ( Brouillet, E; Guyot, MC; Hantraye, P; Mazière, M; Palfi, S; Stutzmann, JM, 1997) |
| "Riluzole treatment almost completely prevented the neuronal degeneration in these brain areas." | 1.30 | Effect of riluzole on the neurological and neuropathological changes in an animal model of cardiac arrest-induced movement disorder. ( Kanthasamy, AG; Nguyen, B; Truong, DD; Yun, RJ, 1999) |
| "Treatment with Riluzole had no significant effect on posttraumatic lesion volume." | 1.29 | Riluzole, a novel neuroprotective agent, attenuates both neurologic motor and cognitive dysfunction following experimental brain injury in the rat. ( McIntosh, TK; Perri, BR; Smith, DH; Stutzmann, JM; Voddi, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Theiss, RD | 1 |
| Hornby, TG | 1 |
| Rymer, WZ | 1 |
| Schmit, BD | 1 |
| McIntosh, TK | 1 |
| Smith, DH | 1 |
| Voddi, M | 1 |
| Perri, BR | 1 |
| Stutzmann, JM | 3 |
| Palfi, S | 2 |
| Riche, D | 1 |
| Brouillet, E | 2 |
| Guyot, MC | 2 |
| Mary, V | 1 |
| Wahl, F | 1 |
| Peschanski, M | 1 |
| Hantraye, P | 2 |
| Mazière, M | 1 |
| Kanthasamy, AG | 1 |
| Yun, RJ | 1 |
| Nguyen, B | 1 |
| Truong, DD | 1 |
1 trial available for riluzole and Movement Disorders
| Article | Year |
|---|---|
Riluzole decreases flexion withdrawal reflex but not voluntary ankle torque in human chronic spinal cord injury.
Topics: Adult; Analysis of Variance; Ankle; Double-Blind Method; Electric Stimulation; Electromyography; Fem | 2011 |
4 other studies available for riluzole and Movement Disorders
| Article | Year |
|---|---|
Riluzole, a novel neuroprotective agent, attenuates both neurologic motor and cognitive dysfunction following experimental brain injury in the rat.
Topics: Animals; Body Water; Brain Edema; Brain Injuries; Cognition Disorders; Male; Movement Disorders; Neu | 1996 |
Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.
Topics: Acetylcholinesterase; Animals; Antiparkinson Agents; Apomorphine; Caudate Nucleus; Corpus Striatum; | 1997 |
Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats.
Topics: Animals; Antihypertensive Agents; Corpus Striatum; Injections, Intraperitoneal; Male; Malonates; Mic | 1997 |
Effect of riluzole on the neurological and neuropathological changes in an animal model of cardiac arrest-induced movement disorder.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Heart Arrest; Histocytochemistry; Male; Movement D | 1999 |